Drug Profile
SAR 164653
Alternative Names: SAR-164653Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Class Cardiovascular therapies
- Mechanism of Action Carboxypeptidase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary hypertension
- Discontinued Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pulmonary-hypertension in USA
- 31 Mar 2013 Discontinued - Phase-I for Cardiovascular disorders (prevention) in USA (unspecified route)
- 31 Mar 2013 Phase-I clinical trials in Pulmonary hypertension in USA (unspecified route)